Meyka Pro banner
Evolus, Inc.

Evolus, Inc. Fundamental Analysis (NASDAQ: EOLS)

EOLSNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$8.21
$0.13(1.56%)
U.S. Market is Open · 14:51

Evolus, Inc. Fundamental Analysis (NASDAQ: EOLS)

Evolus, Inc. (NASDAQ: EOLS) shows moderate financial fundamentals with a PE ratio of -15.76, profit margin of -10.85%, and ROE of 1.23%. The company generates $0.3B in annual revenue with strong year-over-year growth of 11.61%.

Key Strengths

PEG Ratio-0.22
Current Ratio1.70

Areas of Concern

ROE1.23%
Operating Margin-7.33%
We analyze EOLS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 104.8/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
104.8/100

We analyze EOLS's fundamental strength across five key dimensions:

Efficiency Score

Weak

EOLS struggles to generate sufficient returns from assets.

ROA > 10%
-13.84%

Valuation Score

Excellent

EOLS trades at attractive valuation levels.

PE < 25
-15.76
PEG Ratio < 2
-0.22

Growth Score

Moderate

EOLS shows steady but slowing expansion.

Revenue Growth > 5%
11.61%
EPS Growth > 10%
1.23%

Financial Health Score

Excellent

EOLS maintains a strong and stable balance sheet.

Debt/Equity < 1
-5.33
Current Ratio > 1
1.70

Profitability Score

Weak

EOLS struggles to sustain strong margins.

ROE > 15%
123.11%
Net Margin ≥ 15%
-10.85%
Positive Free Cash Flow
No

Key Financial Metrics

Is EOLS Expensive or Cheap?

P/E Ratio

EOLS trades at -15.76 times earnings. This suggests potential undervaluation.

-15.76

PEG Ratio

When adjusting for growth, EOLS's PEG of -0.22 indicates potential undervaluation.

-0.22

Price to Book

The market values Evolus, Inc. at -17.42 times its book value. This may indicate undervaluation.

-17.42

EV/EBITDA

Enterprise value stands at -40.86 times EBITDA. This is generally considered low.

-40.86

How Well Does EOLS Make Money?

Net Profit Margin

For every $100 in sales, Evolus, Inc. keeps $-10.85 as profit after all expenses.

-10.85%

Operating Margin

Core operations generate -7.33 in profit for every $100 in revenue, before interest and taxes.

-7.33%

ROE

Management delivers $1.23 in profit for every $100 of shareholder equity.

1.23%

ROA

Evolus, Inc. generates $-13.84 in profit for every $100 in assets, demonstrating efficient asset deployment.

-13.84%

Following the Money - Real Cash Generation

Operating Cash Flow

Evolus, Inc. generates limited operating cash flow of $-15.36M, signaling weaker underlying cash strength.

$-15.36M

Free Cash Flow

Evolus, Inc. generates weak or negative free cash flow of $-20.15M, restricting financial flexibility.

$-20.15M

FCF Per Share

Each share generates $-0.31 in free cash annually.

$-0.31

FCF Yield

EOLS converts -3.75% of its market value into free cash.

-3.75%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-15.76

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.22

vs 25 benchmark

P/B Ratio

Price to book value ratio

-17.42

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.70

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-5.33

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.70

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.23

vs 25 benchmark

ROA

Return on assets percentage

-0.14

vs 25 benchmark

ROCE

Return on capital employed

-0.16

vs 25 benchmark

How EOLS Stacks Against Its Sector Peers

MetricEOLS ValueSector AveragePerformance
P/E Ratio-15.7631.56 Better (Cheaper)
ROE123.11%441.00% Weak
Net Margin-10.85%18300.00% Weak
Debt/Equity-5.330.73 Strong (Low Leverage)
Current Ratio1.705.63 Neutral
ROA-13.84%1512.00% Weak

EOLS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Evolus, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

175.06%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

83.42%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

61.78%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ